Kimia Farma, South Korea’s SungWun building $10.2M API facility in Indonesia

Spotlight

Kimia Farma, which is owned by the Indonesian government, and South Korea’s SungWun Pharmacopia are teaming up to build a $10.2 million API facility expected to begin operations in 2018.

The 16,400-square-foot facility will initially be able to produce 30 tons of 8 types of API for medicines per year with 23 of those tons slotted for export, the Jakarta Post reported. The plant will also produce 7 types of high function chemicals annually for use in cosmetics and food supplements.

The joint venture is called Kimia Farma Sungwun Pharmacopia.

“At present, the country’s pharmaceutical industry uses around 2,200 types of API,” Rusi Rosman, Kimia Farma’s president director, said. “We aim to produce 50% of them within the next 10 years.”

Additional expansion over the next decade is planned to accommodate the goal set down by Rosman.

Currently, India and China are the two largest suppliers of pharmaceutical raw materials to Indonesia, followed by the U.S. and Europe.

-check out the Jakarta News story

Related article:
B. Braun Medical lands $33M loan to build sterile injection plant in Indonesia

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.